R
Rocío Aller
Researcher at University of Valladolid
Publications - 383
Citations - 5999
Rocío Aller is an academic researcher from University of Valladolid. The author has contributed to research in topics: Population & Insulin resistance. The author has an hindex of 36, co-authored 369 publications receiving 4994 citations. Previous affiliations of Rocío Aller include University of Alcalá & Hanze University of Applied Sciences.
Papers
More filters
Journal Article
Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial.
Rocío Aller,de Luis Da,Olatz Izaola,Rosa Conde,Gonzalez Sagrado M,David Primo,de la Fuente B,Jose Manuel González +7 more
TL;DR: A tablet of 500 million of Lactobacillus bulgaricus and Streptococcus thermophilus, with a randomized clinical design, improved liver aminotransferases levels in patients with NAFLD.
Journal ArticleDOI
The Effects of Duodenal-Jejunal Exclusion on Hormonal Regulation of Glucose Metabolism in Goto-Kakizaki Rats
David Pacheco,D.A. de Luis,Alejandro Romero,Manuel Gonzalez Sagrado,Rosa Conde,Olatz Izaola,Rocío Aller,Alberto Delgado +7 more
TL;DR: Gastrojejunal bypass in a nonobese diabetic model improves glycemic control with a significant decrease in leptin levels, without changes in enteroinsular axis (GLP-1, GIP, glucagons, and insulin levels).
Journal ArticleDOI
Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2
TL;DR: The present study shows that elevation of plasma tHcy levels in type 2 diabetic patients is associated with a higher prevalence of peripheral arteriopathy and nephropathy and the data suggest that hyperhomocysteinemia is not associated with fat mass but it isassociated with high levels of fibrinogen, lipoprotein (a), microalbuminuria, and blood pressure levels.
Journal ArticleDOI
Development and Validation of Hepamet Fibrosis Scoring System A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Javier Ampuero,Raluca Pais,Rocío Aller,Rocío Gallego-Durán,Javier Crespo,Carmelo García-Monzón,Jérôme Boursier,Eduardo Vilar,Salvatore Petta,Ming-Hua Zheng,Desamparados Escudero,Jose Luis Calleja,Patricia Aspichueta,Moisés Diago,José Miguel Rosales,Joan Caballería,Judith Gómez-Camarero,Oreste Lo Iacono,Salvador Benlloch,Agustín Albillos,Juan Turnes,Jesus M. Banales,Vlad Ratziu,Manuel Romero-Gómez,Salvador Agustin,Francisco Jorquera,Rubén Francés,Javier García-Samaniego,Javier Salmerón,Conrado M. Fernández-Rodríguez,Pamela Estévez,Raúl J. Andrade,Germán Soriano,Miguel Fernández-Bermejo,M.T.A. Loste,Rebeca Sigüenza,Aurora Giannetti,Elvira del Pozo Maroto +37 more
TL;DR: The Hepamet fibrosis scoring system had the greatest net benefit in identifying patients who should undergo liver biopsy analysis and led to significant improvements in reclassification, reducing the number of patients with undetermined results to 20% from 30% for the FIB-4 and NFS systems.
Journal ArticleDOI
Effect of soluble fiber intake in lipid and glucose leves in healthy subjects: a randomized clinical trial
Rocío Aller,D.A. de Luis,Olatz Izaola,Fernando la Calle,Lourdes del Olmo,Luis Carlos Martínez Fernández,T. Arranz,J. M. González Hernández +7 more
TL;DR: Modest increases in soluble fiber intake in healthy subjects improved LDL cholesterol and glucose levels and body weight did not change in both groups during treatment.